An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection
Description
CONCLUSION: In acute adult COVID-19 patients presenting within 5 days of symptom onset, leflunomide combined with symptomatic treatment reduced fever duration and viral shedding time.
